NCT00881946View on ClinicalTrials.gov

Repeat Dose Safety Study for Compound to Treat Hematologic Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Hematologic Malignancies
Interventions
DRUG

GSK21110183

Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops

Trial Locations (4)

2031

Prince of Wales Hospital, Sydney

3004

The Alfred Hospital, Melbourne

M5G 2M9

Princess Margaret Hospital, Toronto

110-744

Seoul National University Hospital, Seoul

Sponsors

Lead Sponsor

Accenture
All Listed Sponsors
lead

Accenture

INDUSTRY

NCT00881946 - Repeat Dose Safety Study for Compound to Treat Hematologic Cancer | Biotech Hunter | Biotech Hunter